Advertisement
Canada markets close in 3 hours 18 minutes

  • S&P/TSX

    21,817.35
    -194.37 (-0.88%)
     

  • S&P 500

    5,049.85
    -20.70 (-0.41%)
     

  • DOW

    38,338.18
    -165.51 (-0.43%)
     

  • CAD/USD

    0.7289
    -0.0031 (-0.43%)
     

  • CRUDE OIL

    82.72
    -0.64 (-0.77%)
     

  • Bitcoin CAD

    88,775.24
    -2,677.89 (-2.93%)
     

  • CMC Crypto 200

    1,396.38
    -27.72 (-1.95%)
     

  • GOLD FUTURES

    2,336.20
    -5.90 (-0.25%)
     

  • RUSSELL 2000

    1,985.64
    -17.00 (-0.85%)
     

  • 10-Yr Bond

    4.6500
    +0.0520 (+1.13%)
     

  • NASDAQ

    15,650.63
    -46.00 (-0.29%)
     

  • VOLATILITY

    16.20
    +0.51 (+3.25%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6817
    -0.0019 (-0.28%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

uniQure to Participate in Upcoming Industry Conferences in November

uniQure Inc.
·2 min read

LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

  • The 28th Annual Meeting of the Huntington Study Group (Virtual), November 4 - 6, 2021

    • David Cooper, M.D., vice president of clinical research CNS, will present an overview of the ongoing clinical trials of AMT-130 in Huntington’s Disease, HD-GeneTRX-1 and -2, and participate in a Q&A session on Friday, November 5th at 3:15 p.m. ET.

    • An encore poster presentation entitled, “Demographics and healthcare resource utilization (HRU) in US patients with Huntington’s Disease: data from the Huntington’s Disease Burden of Illness (HDBOI) study” will also be available to view at the Poster Pavilion to registered participants.

  • Virtual Neuroscience 2021 – 50th Annual Meeting, November 8 - 11, 2021

    • Corlieve academic collaborator, Valeria Crepel, Ph.D., will present an encore presentation “CL002, An AAV9 vector expressing engineered miRNA targeting knockdown of GluK2-containing kainite receptors as a novel gene therapy approach for treating intractable temporal lobe epilepsy” on Thursday, November 11th at 10:00 a.m. ET, Session P152: Antiepileptic Therapies IV.

  • Stifel 2021 Virtual Healthcare Conference, November 15 - 17, 2021

    • Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in virtual one-on-one investor meetings on Wednesday, November 17th.

    • A fireside chat with Mr. Kapusta will take place the same day from 10:40 to 11:10 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington's disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:

FOR MEDIA:

Maria E. Cantor

Chiara Russo

Tom Malone

Direct: 339-970-7536

Direct: 617-306-9137

Direct: 339-970-7558

m.cantor@uniQure.com

c.russo@uniQure.com

t.malone@uniQure.com